IBIO

IBIO

USD

iBio Inc. Common Stock

$1.550-0.210 (-11.937%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$1.760

高値

$1.760

安値

$1.515

出来高

1.59M

企業ファンダメンタルズ

時価総額

31.4M

業種

バイオテクノロジー

United States

取引統計

平均出来高

3.38M

取引所

NCM

通貨

USD

52週レンジ

安値 $0.56現在値 $1.550高値 $6.89

関連ニュース

GlobeNewswire

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation New non-human

もっと見る
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
GlobeNewswire

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual Healthcare Innovation

もっと見る
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at

もっと見る
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025